Hangzhou Tigermed Consulting Co Ltd
03347
Company Profile
Business description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
Contact
No. 508 Lujiatan Street
Room 601-610, 6th Floor
Puyan Sub-District, Binjiang District
Zhejiang Province
Hangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
11,130
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,263.15 | 63.86 | 0.78% |
| DAX 40 | 24,731.05 | 114.83 | 0.47% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,350.34 | 22.86 | -0.22% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,204.08 | 165.84 | 1.27% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |